Ten-year Experience with Renal Artery In-stent Restenosis  by Stone, Patrick A. & Aburahma, Ali F.
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 4 Abstracts 1071years) and 125women (mean age, 70.0 11.2 years; PNS).Womenwere
more likely to undergo treatment for critical limb ischemia (87.7% vs 77.7%;
P .028) and less likely to have treatment for claudication (12.3% vs 22.3%;
P  NS). Women were also more likely to undergo balloon angioplasty
(57.5% vs 68.9%; P  .043). However, men were more likely to have
coronary disease, history of coronary bypass grafting, and chronic renal
insufficiency. TransAtlantic Intersociety Consensus distribution, incidence
of smoking, and diabetes were equivalent in both sexes. When adjusted for
comorbidities, women had higher 24-month primary patency rates
(46.0% 6.1% vs 30.4% 5.9%; P .016) and limb salvage rates (87.5%
4.1% vs 82.9% 5.4%; P .041) than men for tibial lesions with concurrent
proximal disease. The difference in 24-month patency between women and
men was more pronounced for isolated tibial lesions (50.1% 10.1% vs
28.8%  10.4%; P  .002). Although the overall complication rates were
similar, women had comparatively higher rates of postoperative access site
thrombosis than men (8.9% vs 0.6%, P  .001).
Conclusions: Overall, endovascular interventions below the knee are
safe and effective in women and should be considered the first-line modality
for the management of critical tibial occlusive disease. However, further
investigation and development of technique to better fit the female anatomy
is necessary to improve the gender-related disparity in access site-related
complications.
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Objective: Minimally invasive endovascular and percutaneous meth-
ods are now available for the management of visceral artery aneurysms and
pseudoaneurysms. This study reviewed our 10-year experience with the
minimally invasive treatment of visceral artery aneurysms.
Methods: The review included all patients evaluated from June 1999
to June 2009 with the diagnosis of aneurysms of the celiac, superior
mesenteric, and inferior mesenteric arteries and their branches. Medical
records were reviewed for demographics, therapy, and results.
Results: Minimally invasive management was attempted in 185
aneurysms in 176 patients (56% men; mean age, 58 years). Intervention
was successful in 182 of 185 (98%) aneurysms in 173 patients. Sixty-three
(34%) aneurysms were located in the splenic artery, 56 (30%) in the
hepatic artery, 28 (15%) in the gastroduodenal, 16 (8.6%) in the pancre-
aticoduodenal, 6 (3.2%) in the superior mesenteric, 4 (2.1%) in the
gastric, 4 (2.1%) in the celiac, 4 (2.1%) in the gastroepiploic, 2 (1%) in the
inferior mesenteric, and 1 (0.5%) in the middle colic artery. Pseudoan-
eurysms were more common than true aneurysms (64% vs 36%). Acute
bleeding was the indication for intervention in 86 aneurysms (46%).
Initial treatment was successful in 177 aneurysms (96%). Five aneurysms
(3%) required additional intervention 30 days for persistent flow or
bleeding. Coiling was the sole technique used in 139 aneurysms (75%)
and was combined with at least one other technique in 20 other aneu-
rysms (11%). Thirty-day aneurysm-related mortality was 1% (2 deaths).
Nine (4.8%) additional deaths occurred during the 30-day follow-up, but
none were related to complications of the aneurysms.
Conclusions: Minimally invasive intervention for visceral artery aneu-
rysms can be used alone or in combination to effectively treat these aneu-
rysms in elective or emergency conditions.
Our Experience with 140 Visceral Artery Stents: Should Celiac Artery
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Objective: Open bypass is the gold standard treatment for mesenteric
ischemia.With the refinement of endovascular therapy, visceral stenting is an
attractive minimally invasive alternative but has limited data, and which
vessel(s) respond best to stenting has not been addressed. This study
compared the outcomes of superior mesenteric artery (SMA) and celiac
artery (CA) stenting.Methods: All consecutive patients who received visceral stenting
between January 2002 and May 2009 were reviewed. Standard statisticalanalysis, including Kaplan-Meier, was performed. Primary patency was
defined as a peak systolic velocity350 cm/s for the CA and450 cm/s
for the SMA. A stenosis of50% at arteriography was considered a loss of
primary patency.
Results: Visceral stents were placed in 140 patients: SMA in 92
(65.7%), CA in 40 (28.6%), and inferior mesenteric artery in 8 (5.7%). There
were 29men (20.7%) and 111 women (79.3%) with amean age of 72.9 years
(range, 20.5-93.9 years). Mean follow-up was 12.8 months. Technical
success was 100% for all. The 30-day mortality rate was 0% for the SMA and
5% for the CA. One-year primary patency was 55% for the SMA and 17% for
the CA (P  .0001). Loss of CA primary patency was associated with
ischemic heart disease (P .05), stent diameter of6 mm (P .042), and
age 50 years (P  .038). These factors did not correlate with loss of
primary patency for the SMA (Fig).
Conclusions: Visceral stenting has an exceptional technical success
rate, with low procedural mortality. Primary patency of the SMA group
was significantly higher than that for the CA. Our data suggest that CA
stenosis, especially in young patients and those with small vessels, does
not respond well to stenting. Therefore, the practice of celiac artery
stenting should be abandoned.
Ten-year Experience with Renal Artery In-stent Restenosis
Patrick A. Stone, MD, and Ali F. Aburahma, MD, West Virginia University,
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Objective: Endovascular interventions for symptomatic renal artery
stenosis have become the first-line treatment. Limited data are available for
the long-term outcome of secondary interventions of recurrent renal artery
stenosis after stenting.
Methods:This was a retrospective analysis of a 10-year experience with
percutaneous renal artery interventions. Only patients presenting with re-
current symptomatic stenosis were reviewed. End points analyzed included
freedom from tertiary procedures, a decrease in baseline renal function
20%, patency confirmed by duplex imaging, freedom from hemodialysis,
and patient survival.
Results: The review included 948 patients with 1150 renal arteries
treated; of these, 123 arteries in 108 patients (68.9% women) presented with
symptomatic recurrent stenosis, comprising recurrent hypertension in 97%
and renal insufficiency in 67%. The average age was 68.9. Mean follow-up
was 30 months (range, 1.2-104.7 months) for patency and 56 months
(range, 6.2-112.7 months) for creatinine level. Secondary interventions
included percutaneous transluminal angioplasty (PTA) only in 27, PTAwith
cutting balloon in 9, repeat renal artery stenting in 80, and drug-eluting
stent (DES) placement in 7. After secondary interventions, 20 of the 123
arteries (16.3%) in 18 patients required tertiary interventions. Freedom from
tertiary interventions was similar among treatment modalities, with PTA,
PTA-cutting balloon, stent, and DES groups having 81.5%, 100%, 83.8%,
and 71.4%, respectively, of patients remaining procedure free. Forty patients
(37%) had a decrease in renal function 20%, and 24 (22.2%) remained or
Fig.progressed to renal failure (estimated glomerular filtration rate 30%), and
eight ultimately required hemodialysis. Patient survival was 72.8% at 5 years.
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ilar functional results as those seen for the primary intervention. Angioplasty
appears to have similar results to secondary stenting.
Differences in Anatomy and Outcomes in Patients Treated with Open
Mesenteric Revascularization Before and After the Endovascular Era
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Objectives: Endovascular revascularization (ER) is currently the pre-
ferred treatment method in patients with chronic mesenteric ischemia
(CMI). The aim of this study was to compare differences in clinical charac-
teristics, anatomy, and outcomes in patients treated with open mesenteric
revascularization (OR) before and after the endovascular era.
Methods: Two-hundred and forty-one patients treated for CMI
(51.8% ER; 48.2% OR) between 1998 and 2009 were entered into a
prospective database. Since 2002, ER was used in 102 patients (63.8%) and
OR in 58 (36.3%) because ER was not possible, failed, or the patient had
unfavorable lesions. We reviewed the clinical data and outcomes of patients
treated with OR before (group A) and after (group B) the preferential use of
ER in 2002. Computed tomography angiography with centerline measure-
ment and conventional angiography were used to assess differences in
anatomy.
Results: OR was used to treat 58 patients in group A and 58 in group
B. Both groups had similar demographics, risk factors, and clinical presen-
tation, with the exception of more (P .05) cardiac interventions, dysrhyth-
mias, abdominal pain, and food fear in group B. Patients in group B had
more extensive disease, including more superior mesenteric artery (SMA)
occlusions (45% vs 67%, P  .02). There were no differences in operative
mortality (1.7% vs 3.4%), complications (43% vs 53%), and length of stay
(both 12  1 days) for group A and B, respectively (P  NS). Symptom
improvement was noted in 88% of group A patients and in 86% of group
B patients (P  NS). Mean follow up was 56  7 months in group A and
22 3 months in group B (P .01). At 1-year, there were no differences in
patency and recurrence rates between groups.
Conclusions:Open mesenteric revascularization is currently indicated
in about 36% of patients with CMI. Despite the presence of more extensive
mesenteric disease in patients currently treated with OR, outcomes have not
changed compared with those achieved before the preferential use of mes-
enteric stents.
Comparison of Modern Open Repair of Infrarenal and Pararenal
Abdominal Aortic Aneurysms: Early Outcomes and Late Renal
Dysfunction
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Objectives: Open repair of infrarenal (IAAA) and pararenal (PAAA)
abdominal aortic aneurysms (AAA) continue to be performed in an endo-
vascular era. This study was conducted to review contemporary results of
elective open AAA repairs and determine predictors of death and acute and
late renal dysfunction.
Methods: A retrospective single-institution review identified 417 con-
secutive patients with available data who underwent elective open AAA
repairs between July 2000 and June 2007. Demographic, preoperative,
intraoperative, and postoperative variables were collected. Renal dysfunction
was defined as an increase in creatinine of 0.5 mg/dL from baseline.
Multiple logistic regression models were used to identify predictors of death
and renal dysfunction.
Results: A total of 232 IAAA (55.6%) and 185 PAAA (44.4%) repairs
(156 juxtarenal [JAAA] and 29 suprarenal [SAAA]) were performed in 294
men and 123 women with a mean age of 71.7 years. Concomitant renal
artery reconstruction was performed in 20 patients. Baseline characteristics,
including creatinine levels, did not differ among groups, except for age (70.4
years, IAAA; 73.1 years, JAAA; 73.7 years, SAAA; P  .006). Overall
operative mortality was 4.8%: IAAA, 3.9%; JAAA, 5.1%; and SAAA, 10.3%
(P  .30). Postoperative myocardial infarction and pulmonary complica-
tions were independent predictors of in-hospital death, but type of AAA was
not. Occurrence of postoperative renal dysfunction increased with the extent
of the AAA; 15.4% IAAA, 32.3% JAAA, and 48.3% SAAA (P  .001),
requiring new-onset hemodialysis in 0.9% (2 of 226), 1.3% (2 of 155), and
10.7% (3 of 28), respectively (P .001). The incidence of renal dysfunction
was, respectively, 1.7%, 6.0%, and 15.4% (P  .038) at 1 year and 5.6%,
16.7%, and 37.5% (P .003) at the last follow-up, without development of
hemodialysis dependence. Independent predictors of early renal dysfunctionwere PAAA, hypertension, and AAA size; and of late renal dysfunction,
SAAA.
Conclusions: Open PAAA repair can be done without a significant
increase in death compared with open IAAA repairs. Acute and late renal
dysfunction is related to the extent of AAA and warrants close surveillance.
These data may serve as a benchmark against which outcomes of endovas-
cular aneurysm repair are compared.
Hemodialysis Reliable Outflow (HeRO) Catheter Outcomes in Pa-
tients with Long-standing Renal Failure: Optimizing Performance
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Objectives: Owing to the increasing population of access-challenged
dialysis patients, the Hemodialysis Reliable Outflow (HeRO) device is
becoming a more recognized alternative option for patients who have a
tunneled dialysis catheter (TDC).We have developed criteria and risk factors
that we hope will improve patency, reduce infection, and ultimately improve
the performance of the HeRO device in this high-risk population.
Methods: All HeRO implants fromMay 2008 through June 2009 at a
single institution were retrospectively reviewed. Patient demographics, his-
tory, and implant success were evaluated. Cephalosporin was the preferred
prophylactic antibiotic. Primary outcomes were successful implantation,
patency rates, and infection. Secondary outcomes were morbidity and death.
Results: The HeRO device was successfully implanted in 40 of 42
procedures (95%). Mean age was 57.5 years. Most (95%) were African
American with at least two major comorbidities, and 39 patients were
TDC-dependent. Mean duration on hemodialysis was 7.6 years. Mean
number of hemodialysis catheters, arteriovenous grafts, and arteriovenous
fistulae per patient before implant were 7.2, 1.4, and 1.9, respectively. The
overall infection rate was 20% (n  8), with a device-adjusted infection rate
of 1.09/1000 device-days, with seven occurring in patients with insulin-
dependent diabetes (17.5% vs 2.5%, P  .007). One-month patency was
90%, with 21 (53%) using the HeRO for dialysis after a mean follow-up of
4.1 months. Device thrombosis was less likely to develop in patients taking
Plavix (0% vs 32.5%, P .025). The number of prior access procedures (5)
was associated with device thrombosis (2.5% vs 45%, P  .005) and device-
related infections (0% vs 20%, P .021). The 30-daymortality was 13% (n
5), which was not related to the procedure. Overall 1-year survival was
72.5%.
Conclusions: In this high-risk patient population, the HeRO device
can be placed successfully, with low morbidity. Factors that may optimize
performance include the postoperative use of Plavix, use of the device earlier
in traditional dialysis-access algorithms, and possibly, the perioperative
administration of broad-spectrum antibiotics.
Existing Trauma and Critical Care Scoring Systems Underestimate
Mortality Among Vascular Trauma Patients
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Objectives: The effect of vascular injuries on patient mortality has not
been well documented in multitrauma patients. This study sought to deter-
mine whether the presence of vascular injury negatively affected patient
outcome compared with nonvascular trauma (NVT) patients and the utility
of existing severity scoring systems in predicting death among vascular
trauma (VT) patients.
Methods: The trauma database from January 2005 to December 2007
was retrospectively reviewed. Demographics, Injury Severity Scores (ISS),
Revised Trauma Scores (RTS), Acute Physiology and Chronic Health
Evaluation (APACHE) II scores, and death were compared with control
patients selected from a matching cohort based on ISS. Comparisons were
made between VT and NVT patients grouped into categories of severity
based on the scoring systems. These systems have been shown in the
literature to be predictive of mortality. Statistical analysis was performed
using 2 analysis and t tests.
Results:We identified 50 VT and 50 NVT patients, with no significant
differences in age, gender, mechanism of injury, ISS, or RTS. The mean
APACHE II score was 12.3 in VT patients vs 8.8 in NVT patients (P .05).
Overall mortality was 24% in VT patients vs 11.8% in NVT patients, but this
did not reach statistical significance (P .108). VT patients with an RTS5
had a higher mortality rate (26% vs 2.2%, P  .007). VT also predicted
higher mortality in patients with an ISS 24 (61% vs 28.6%, P  .04).
Finally, VT patients with an APACHE II score 14 also had a higher
mortality rate (18.2% vs 0%, P  .007; Table).
